Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
This Week's Featured Article Why 2 Small Biotechs May Hold the Key to New Cancer TreatmentsReported by Nathan Reiff. Article Published: 3/12/2026. 
Article Highlights - Iovance and ImmunityBio each have a leading oncology product that has helped to massively boost sales and share prices in recent quarters.
- Despite major gains in recent trading, IOVA and IBRX shares still have at least 70% in upside potential going forward, according to analysts.
- Profitability remains a concern for both companies, even as sales of their top cancer drugs have surged.
Cancer remains one of the greatest medical challenges for biotechnology firms, even as the oncology medicine market is projected to reach $366 billion over the next eight years. Companies often take a niche approach, developing medicines that target specific cancers with tailored mechanisms. Several promising treatments have shown strong potential—and with that comes the possibility of significant sales. Two smaller biotech companies are seeing notable share-price momentum thanks to their leading oncology medicines. Beyond their therapeutic potential, these drugs could help the firms move beyond penny-stock status toward longer-term stability and eventual profitability. That said, both remain typical high-risk biotech investments: they carry meaningful challenges but also the potential for outsized rewards for investors willing to accept the risk. Iovance's Powerful Cancer Drug Is Growing, But Production Challenges Are a Hurdle In 1934, the government executed a legal maneuver that transferred billions in wealth overnight—most Americans had no idea it was coming, a small group who saw it early walked away wealthy, and everyone else paid for it. Trump has the same legal authority today, advisors close to the administration believe he's considering using it, and if he does, the transfer happens fast with the window to be on the right side of it already closing. Get the free report on how to position yourself now Iovance Biotherapeutics Inc. (NASDAQ: IOVA) defied market trends in early March, surging nearly 37% in a week when the S&P 500 fell about 1%. That added to a year-to-date rally that has more than doubled the stock. Still, with a consensus price target of $8.88, Wall Street expects further upside—this target implies roughly 71% more gains could be available. The primary catalyst for Iovance's move is Amtagvi, a T-cell immunotherapy for certain types of melanoma. Amtagvi was approved in the United States for melanoma in 2024 and has been gaining momentum—in sales and with additional approvals possible in the E.U., U.K., and elsewhere. When administered with Proleukin, the company's IL‑2 immunotherapy, management believes Amtagvi could achieve more than $1 billion in peak U.S. sales. Amtagvi's potential may extend beyond melanoma: the drug received FDA Fast Track designation for non-small cell lung cancer and is being evaluated for other cancer types. Some of Iovance's recent outperformance also reflects its Q4 2025 earnings report, issued in late February, in which the company posted smaller-than-expected losses per share and reported $5 million in revenue. For the full year, revenue rose roughly 30% year over year. Iovance is a small-cap company (about $2 billion) and is considered a penny stock. Despite the substantial rally this year, analysts remain cautious: roughly half of its dozen or so ratings are Hold or Sell. Risks remain high beyond the usual caveats for smaller biotech firms—Amtagvi is personalized, costly and complex to manufacture, which could limit margins and delay profitability even as demand grows. Massive Sales Growth for ImmunityBio's Bladder Cancer Drug Although ImmunityBio Inc. (NASDAQ: IBRX) fell about 20% in March, its year-to-date performance far outpaces Iovance's. IBRX shares are up nearly 300% in 2026 alone, and analysts remain optimistic: the consensus price target of $13.60 implies roughly 70% upside from current levels even after the run-up. ImmunityBio's leading product and primary growth driver is Anktiva, a treatment for certain types of bladder cancer. In February, shares spiked after the European regulator granted the drug conditional marketing authorization—the latest in a string of approvals worldwide. Anktiva is already driving revenue: the drug generated $113 million in sales last year, a roughly 700% year-over-year increase. Like Amtagvi, Anktiva may have potential in other cancer types, and ImmunityBio is actively exploring additional indications. Despite the dramatic gains over recent quarters, IBRX remains a speculative investment. The company posted a full-year net loss of $351 million for 2025 as R&D expenses continue to climb. Wall Street analysts are, however, relatively bullish compared with their view on Iovance—six of seven rate IBRX a Buy or equivalent.
| 
